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1. INTRODUCTION 
 
1.1. GENERAL INTRODUCTION 
 
According to the latest world cancer statistics published by the International 
Agency for Research on Cancer (IARC) in 2012, breast cancer represents 11,9% of 
diagnosed cancers, which means approximately 1.7 million new patients every year 
worldwide. This makes breast cancer the second most common malignancy, and the 
most frequently diagnosed cancer among women. Breast cancer is also the leading 
cause of cancer death among women and accounts for approximately 520 000 deaths 
per year. Since the previous (2008) IARC world cancer statistics, the incidence of 
breast cancer has increased by 20%, while mortality has increased by 14% [1, 2]. 
There are different approaches to the classification of breast cancer based on 
conventional methods like histopathological/morphological appearance, degree of 
differentiation (grade), extent of tumor spread (stage), but there are also relatively 
new categorizations, e.g. the ones based on gene expression profiling and molecular 
subtyping. Every approach tries to stratify breast cancer by risk and prognosis. The 
more recent classifications try to categorize the disease at the molecular level and give 
important predictive information on the potential responsiveness of the tumors to 
different therapeutic modalities. 
As concerns the histopathological classification according to the 4th edition of 
the World Health Organization (WHO) Classification of Tumors of the Breast, 
invasive cancers not fulfilling the strict definition of one of the many specific 
histological types (e.g. lobular, tubular, mucinous etc.) are designated as invasive 
carcinoma of no special type (NST), formerly called invasive ductal carcinoma not 
otherwise specified. NST is the most common histological type comprising 
approximately 60% of invasive breast carcinomas. If a specific growth pattern of 
breast cancer represents more than 90% of the tumor, it can be classified as being of a 
specific type. These types of breast cancer are less frequently encountered, with 
invasive lobular carcinoma (ILC) being the most common, representing 10% of 
mammary cancers with other special types accounting for less than 1 to 5% each [3, 
4]. 
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Classification of tumors according to the level of differentiation is called 
grading and is one of the oldest and most widely accepted histologic tools to predict 
the prognosis of a malignant neoplasm. Grading of cancers can be performed on the 
basis of histologic or nuclear features or both. In current breast pathology practice, the 
most frequently used three-tiered (grade 1-3) grading scale is the so-called combined 
histological grade (the Nottingham score system, or the Elston-Ellis modification of 
the Scarff-Bloom-Richardson grading system). This method is based on the complex 
evaluation and semiquantitative scoring of ”tubule formation” (glandular 
differentiation) and nuclear morphology combined with the mitotic activity of the 
tumor [5-7]. 
A staging system is a standardized method to describe the anatomic extent of a 
disease, i.e. how far cancer has spread. The most common system used is the TMN 
staging system, which classifies cancers according to their local size and some 
features of advanced disease (T category), lymph node involvement (N category) and 
distant spread (M category). Staging can be performed by physical examination, 
radiologic imaging studies and pathologic examination following breast surgery. 
Pathologic evaluation is considered to be the most accurate method for the staging of 
tumors [8, 9]. 
Molecular subtypes of breast cancer have been identified using gene 
expression profiling. The most reproducibly identified molecular subtypes are the 
luminal A, luminal B, human epidermal growth factor receptor (HER2)-enriched and 
basal-like groups. Luminal types are characterized by estrogen receptor (ER) driven 
carcinogenesis, whereas the latter two groups are hormone receptor independent and 
cluster as ER-negative subtypes. The molecular type of breast cancer is a valuable 
information to assess prognosis and determine the appropriate therapy [10-12]. 
As in routine histopathology practice gene expression profiling based breast 
cancer classification is not yet widely accessible, an approximations of molecular 
subtypes using immunohistochemistry (IHC) and in situ hybridization (ISH) has been 
proposed by Goldhirsch et al [13]. This surrogate IHC method for the determination 
of molecular subtypes uses ER, progesterone receptor (PR), HER2 and Ki67 
antibodies. The hormone receptor (ER/PR) positive luminal-like types are designated 
as luminal B-like on the basis of a high proliferation rate, using Ki-67, or HER2 
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overexpression/amplification, while luminal carcinomas with low Ki67 labeling index 
(LI) and HER2-negativity fall into the luminal A-like group. Hormone receptor 
negative cases overexpressing HER2 represent a so-called HER2-enriched type. 
Although the basal-like molecular type is frequently correlated with an ER, PR and 
HER2 negative IHC profile designated as triple-negative breast cancer (TNBC), the 
two categories cannot be equated. Many TNBCs do not fall into the basal-like breast 
cancer (BLBC) type [13, 14]. 
TNBC represents about 15% of breast malignancies [15]. By their negativity 
for the above-mentioned predictive factors, TNBCs are unsuitable for systemic 
therapies targeting the ER or HER2 pathways, and therefore identification of subsets 
that may be responsive to future targeted therapies is important. 
According to the definition of the WHO, tumors made up of cells characterized by 
abundant, intensely eosinophilic, granular or sometimes vacuolated cytoplasm, large 
nuclei and prominent nucleoli are designated as invasive carcinomas with apocrine 
differentiation or simply invasive apocrine carcinomas. ER and PR negativity, 
androgen receptor- (AR) positivity [16], with the co-expression of gross cystic disease 
fluid protein-15 (GCDFP-15) are considered as IHC criteria of apocrine 
differentiation. Somewhat more than half of apocrine carcinomas represent a 
subgroup of TNBCs and nearly half of them overexpress HER2 [17]. Recently a gene 
expression profile based category of molecular apocrine tumors has also been 
introduced [18]. Apocrine carcinomas represent a peculiar ER-negative, but AR-
positive molecular type of breast malignancies. These tumors are more closely related 
to luminal breast carcinomas, and they have a better prognosis [15, 19]. According to 
Lehmann et al, TNBCs can be divided into at least six distinct relatively stable 
molecular subtypes [19], and one of these is the luminal androgen receptor positive 
(LAR) set of cancers, to which many apocrine carcinomas belong to. Despite the ER 
and PR negativity, LAR tumors are characterized by AR positivity and active steroid 
hormone metabolism [20], which suggests that this subset of TNBCs may be 
responsive to some specific hormonal therapeutic options. 
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1.2. THE INVOLVEMENT OF GROWTH HORMONE-RELEASING 
HORMONE (GHRH) IN CARCINOGENESIS 
 
Growth hormone-releasing hormone (GHRH) has been implicated in 
carcinogenesis as a growth factor acting both indirectly through the neuroendocrine 
axis involving the pituitary release of growth hormone (GH) with subsequent 
expression of insulin-like growth factor 1 (IGF-1) in the liver, and more significantly 
directly through autocrine and paracrine mechanisms (Figure 1). 
 
Figure 1. (A) Indirect carcinogenetic pathway by the stimulation of pituitary 
GHRH-receptors and the neuroendocrine axis.  (B) Direct autocrine and paracrine 
pathways. 
Many cancers of extrapituitary tissues, including breast carcinomas, express 
GHRH and GHRH receptors (GHRH-R) [21-23]. The presence of both the full-length 
pituitary GHRH receptor (pGHRH-R) and its splice variants, predominantly the splice 
variant 1 (SV1) have been documented in breast cancer [22, 24-26]. As evidence of 
an autocrine/paracrine regulatory mechanism, it has been shown that the knocking 
down of the GHRH gene expression in breast cancer cell lines with small interfering 
ribonucleic acid (SiRNA) results in reduced cellular proliferation [27]. Similar effects 
are produced in prostate cancer and non-small cell lung cancer cell lines [23, 27]. As 
additional support for an autocrine/paracrine regulation, the transfection of the MCF7 
cells (originally devoid of GHRH-R) with the GHRH-R, results in increased cellular 
A B 
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proliferation after the addition of exogenous GHRH. This increase in proliferation is 
even greater when the transfection involves the SV1 receptor [28]. The transfection of 
MCF-7 cells with the SV1 receptor results in increased proliferation even without the 
addition of exogenous GHRH, suggesting a GHRH-independent activation of this 
truncated receptor [28]. Furthermore, GHRH-R antagonists have been found to be 
effective in the reduction of invasive and metastatic potential of human cancer cell 
lines in vitro by modifying cellular adhesion, migration and survival [29]. The 
antagonistic analogs of GHRH have been reported to consistently reduce or abolish 
the growth of several breast cancer models [26, 30, 31], and therefore such 
antagonists have been proposed as potential targeted therapeutic agents for breast 
carcinoma. 
The presence of the pGHRH-R and/or the SV1 receptor in cancer cells has 
been demonstrated by different techniques including RT-PCR [22, 24, 31, 32], 
Western blotting [26, 32], in situ hybridization [33], immunohistochemistry [25, 28, 
33, 34] and radioreceptor assays [35]. GHRH-Rs have been demonstrated in ER 
dependent as well as independent breast carcinoma cell lines [31], in both ductal NST 
carcinomas (in various histological grades) and ILCs [25, 33]. 
The presence of GHRH-R in breast carcinomas may therefore have potential 
systemic treatment implications with agents targeting the GHRH-R pathway. 
Although the presence of GHRH-R in breast cancer was documented before, no 
previous study systematically investigated the expression of the receptor in different 
subtypes of breast cancer before. 
 
1.3. THE p53 TUMOR SUPRESSOR GENE FAMILY 
 
The tumor suppressor gene family “p53” includes transformation-related 
protein 53 (TP53), transformation-related protein 63 (TP63) and transformation-
related protein 73 (TP73) genes that are responsible for encoding transcription factor 
proteins labelled as tumor protein 53 (p53), tumor protein 63 (p63) and tumor protein 
73 (p73), respectively [36, 37]. 
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The tumor suppressor p53 enforces its anti-oncogenic functions by arresting 
the cell cycle, initiating apoptosis and facilitating DNA repair through its effects on 
the transcription of other tumor suppressor genes [38, 39]. 
In contrast to the ubiquitous expression of p53, p63 and p73 are expressed in 
limited tissue types and share partially overlapping functions with p53 by 
upregulating numerous p53 target genes [40, 41]. TP63 encodes for three main splice 
variants TAp63α, TAp63 and TAp63γ, which differ in their carboxy-terminal 
domains and ΔNp63 also known as p40 isoforms resulting from alternative promoter 
usage which lack the N-terminal (transcription activation, TA) domain [42] (Figure 
2.). TAp63α and TAp63γ trigger anti-proliferative effect rendering them tumor 
suppressor proteins whereas the p40 isoform works as an oncoprotein and suppresses 
the transactivation activity of both TAp63 and p53 [43]. 
 
Figure 2. Schematic structure of the p53, p63 and p40 (ΔNp63 isoform) 
proteins. 
p63 is expressed in basal epithelia in a restricted pattern, and is utilized 
primarily as a marker of squamous [44], myoepithelial (MEC) [45], prostate basal 
[46] and urothelial cells [47] in current surgical pathology practice. 
In comparison to other MEC markers, p63 is slightly less sensitive but more 
specific than smooth muscle actin, smooth muscle myosin heavy chain and calponin 
[48]. p40 is the newest member of the family being used as an IHC marker and is 
reported to be superior to p63 for squamous differentiation in the differential 
diagnosis of non-small cell lung cancer [49]. 
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Many myoepithelial / basal cell markers are also expressed in a group of breast 
carcinomas representing a basal-like nature or myoepithelial differentiation [50]. The 
most widely accepted surrogate IHC markers to identify BLBCs amongst TNBCs are 
cytokeratin (CK) 5, 14, 17 and epidermal growth factor receptor (EGFR)[51, 52]. 
Although compared to CK5, p63 is only infrequently expressed by BLBCs, there are 
only scant data on the expression of p40 in these tumors. 
 
1.4. EXPRESSION OF CD10 IN BREAST TISSUE 
 
Cluster differentiation 10 (CD10) also known as neprilysin, enkephalinase, 
common acute lymphoblastic leukemia antigen (CALLA) or neutral endopeptidase 
(NEP) is a membrane-bound zinc-dependent metalloprotease enzyme that degrades a 
number of small secreted peptides [53, 54]. It is a fairly ubiquitous enzyme found on 
the surface of many different cell types including pre-B cells, germinal center B cells, 
neutrophils, T-cell precursors and epithelial cells of the kidney, stomach, colon, 
prostate and liver canaliculi as well as in stromal cells of the endometrium and 
myofibroblasts [55]. In humans, CD10-related DNA sequences are found on 
chromosome 3 [56]. Three different splice variants of CD10 have been identified, 
suggesting that CD10 expression may be controlled in a tissue specific manner [57]. 
Physiologically, CD10 plays an important role in the metabolism of signaling 
peptides like natriuretic peptides, angiotensins, bradykinin, endothelin, enkephalins, 
oxytocin, tachykinins, substance P, calcitonin gene-related peptide (CGRP) and 
vasoactive intestinal polypeptide (VIP), involving it in the extracellular regulation of 
a number of signaling pathways of the mammalian nervous, cardiovascular, 
inflammatory and immune systems [53, 55]. CD10 is involved in the pathogenesis of 
numerous non-neoplastic diseases such as diabetic nephropathy [58] and Alzheimer’s 
disease [59]. With IHC, it can be detected in many hematological malignancies [60-
62], soft tissue neoplasia (e.g. pleiomorphic undifferentiated sarcoma, fibrosarcomas, 
leiomyosarcomas and malignant peripheral nerve sheath tumors) [63], as well as in 
carcinomas of different organs, like the skin [64, 65], the lungs [66.], the pancreas 
[67], the liver [68], the stomach [69], the uterine cervix [70], the kidneys [71], the 
urinary bladder [72] and the prostate [73]. Such a wide spectrum of expression may 
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suggest a limitation in the usefulness of CD10 immunostaining in routine diagnostic 
pathology. 
As concerns the breast, CD10 has an important role in its development 
through modulation of cell growth and differentiation, and by having effects on 
epithelial-mesenchymal morphogenesis [74, 75]. CD10 is not only expressed by 
MECs but can also be detected on the surface of mammary stem cells, early common 
breast progenitor cells and in myoepithelial progenitors. CD10 protease maintains the 
early progenitor population in the human mammary lineage by degrading signaling 
proteins that would otherwise promote maturation [76]. A study using a mouse model 
has shown the involvement of oxytocin, a peptide cleaved by CD10, in the 
differentiation of MECs [77]. CD10 also has prognostic implications; its expression in 
breast tumor stromal cells is correlated with ER negativity, a higher grade and poor 
prognosis [78, 79]. CD10 has been shown to discriminate between benign, borderline 
and malignant phyllodes tumors of the breast and its expression has been found on 
IHC to correlate significantly with the occurrence of distant metastasis [80]. 
In diagnostic breast histopathology, CD10 IHC is used to identify MECs. 
Although MECs around normal structures (ducts and lobules) are nicely highlighted 
by this marker, in pathologic conditions such as ductal carcinoma in situ (DCIS), 
CD10 has a relatively low sensitivity as an MEC marker [81], and its specificity also 
seems compromised by the fact that, rarely, tumor cells also stain with the antibody 
[82], although the pattern of staining in the neoplastic mammary epithelium has not 
been widely studied. 
Apocrine epithelium has been described to be positive for CD10 [83], and 
Kalof et al. [81] clearly documented the consistent luminal staining of apocrine 
metaplasia. While studying breast lesions immunostained for CD10 as an MEC 
marker, we also recognized that paratumoral apocrine cysts demonstrated a strong, 
predominantly apical reaction, and we have also found traces of this staining pattern 
in the literature [81, 83]. To our knowledge, no previous studies have systematically 
examined CD10 expression of apocrine lesions. 
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2. AIMS 
 
The aims of the present thesis are listed as follows: 
To analyze a series of breast carcinomas for the expression of GHRH-R and to 
correlate the presence of these receptors to histological features and morphological or 
biological subtypes of breast cancers. 
To investigate a series of apocrine breast carcinomas for the expression of 
GHRH-R, because of the positive immunostaining of paratumoral benign apocrine 
epithelium noted during the course of the study. 
To test the maintenance of GHRH-R status of the primary tumors in lymph 
node metastases as a possible GHRH-R antagonist could also be useful in the 
treatment of metastatic patients. 
To compare the expression of p40 versus p63 in the MEC component of 
normal breast structures and in breast lesions with occasional absence of or decrease 
in the staining for some other MEC markers and to see whether p40 was also superior 
to p63 as a MEC marker. 
To assess and compare the expression of p63 versus p40 in TNBCs showing 
CK5 expression, i.e. in tumors that would be classified as BLBCs by the surrogate 
IHC based approach. 
To analyze a series of breast lesions with apocrine differentiation for the 
expression of CD10, both in the epithelial and the myoepithelial components and to 
explore how the immunostaining varied in benign, in situ and invasive malignant 
lesions. 
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3. MATERIALS AND METHODS 
 
3.1. GENERAL ASPECTS 
 
The conducted GHRH-R, p40 and CD10 expression related research was all 
carried out retrospectively using IHC. 
Tissue blocks obtained either from breast conserving surgery or total 
mastectomy specimens mainly from the archives of the Bács-Kiskun County 
Teaching Hospital and University of Szeged were used with the following exceptions: 
 For the GHRH-R expression study, breast carcinomas with apocrine 
differentiation were also obtained from the Department of Medical 
Sciences, University of Turin, Via Santena 7, Turin 10126, Italy. 
 For the p40 expression study, blocks of adenomyoepithelial lesions were 
also obtained from the Department of Pathology, University Hospital 
Center Sestre milosrdnice of Zagreb and the 2nd Department of Pathology 
of Semmelweis University, Budapest. 
Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin 
(FFPE). Composite tissue microarray (TMA) paraffin blocks were also built up by 
extracting smaller cylindrical tissue samples from the donor blocks of multiple breast 
cancer cases. Four to five micrometer-thick whole tissue sections and similar sections 
of TMA blocks were used for IHC. Deparaffinization and rehydration at room 
temperature was followed by heat induced epitope retrieval (HIER) with the PT Link 
system (“Target retrieval solution”, pH 9.0 for 30 min at 94°C - DAKO, Glostrup, 
Denmark). After being rinsed with Tris buffer saline - EnVision FLEX Wash (TBS), 
the sections were placed in a Dako Autostainer Link 48 for endogenous peroxidase 
blockage and staining. Diaminobenzidine (DAB; Dako, Glostrup, Denmark) or VIP 
(Vector Laboratories, Burlingame, CA, USA) were used as chromogens. The sections 
were then counterstained with Mayer's hematoxylin, dehydrated, cleared in xylene, 
and mounted. Negative controls were carried out by omitting the primary antibody. 
Primary antibodies used in the different studies and the details of the applied 
protocols are listed in Table 1.  
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Antibody Name 
(Clone) 
Immunogen 
epitope 
Company Dilution Incubation 
time / 
temperature 
GHRH-R ab 76263 
(polyclonal) 
C-terminal 
domain (50 
amino acid) 
Abcam (Cambridge, UK) 1:250 60 min / 
room 
temperature 
(RT) 
ER SP1 C-terminal 
domain 
Thermo Scientific, 
(Waltham, MA, USA) 
1:200 30 min/RT 
PR RB-9017 
(polyclonal) 
Not specified Thermo Scientific, 
(Waltham, MA, USA) 
1:100 60 min/RT 
HER2 SP3 Cytoplasmic 
domain 
Biocare Medical 
(Concord, CA, USA) 
1:100 60 min/RT 
Ki-67 MIB-1 Not specified Dako (Glostrup, 
Denmark) 
1:100 30 min/RT 
 
AR F39.4.1 Amino acids 
301-320 
BioGenex, (Fremont, 
CA, USA) 
1:50 30 min/RT 
GCDFP-
15 
23A3 Not specified Cell Marque, (Rocklin, 
CA, USA) 
1:200 30 min/RT 
p40 BC28 Amino acids 5-
17 
BioCare (Concord, CA, 
USA) 
1:200 30 min/RT 
p63 4A4 TA domain Thermo Scientific, 
(Waltham, MA, USA) 
1:400 30 min/RT 
CK5 XM26 C-terminal 
domain  
BioCare (Concord, CA, 
USA) 
1:1 
Ready to 
use 
60 min/RT 
CD10 56C6 Not specified Cell Marque (Rocklin, 
CA, USA) 
Dako (Glostrup, 
Denmark) 
1:50 
1:1 
Ready to 
use 
30 min/RT 
Table 1. List and applied protocols of primary antibodies. 
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All specimens were evaluated by two pathologists (BK, GC) in parallel using 
a double headed microscope. 
Since all patient and disease information was gathered anonymously and 
retrospectively with no influence on patient outcome or treatment, no ethical 
permission was deemed necessary according to local regulations. For the p40 related 
study, involving TMA fabrication from a few tumors, the institutional review board of 
the Bács-Kiskun County Teaching Hospital was consulted, and the study was 
considered non-interventional and approved. 
 
3.2. THE EXPRESSION OF GHRH-R IN DIFFERENT TYPES OF 
BREAST CARCINOMAS 
 
In this retrospective study, tissue blocks of 100 breast cancer cases were used. 
Carcinomas ≤2 cm (pT1 tumors) [8, 9], were preferentially included in the study to 
limit the effect of tumor heterogeneity. Groups of different histological, molecular 
and clinicopathological types of breast cancer were selected. Histological types 
included invasive tubular, ductal / NST carcinomas and ILCs as defined by the WHO 
classification of breast tumors [3]. Grading was performed on the basis of the 
Nottingham scheme [6]. Molecular types were determined by means of the surrogate 
IHC-based approach as proposed by the St Gallen consensus meeting report valid at 
the time of performing the study [13]. On this basis, ER-positive tumors were 
classified as luminal A if they were HER2-negative and had a Ki-67 LI <14%; they 
were labeled as luminal B if they were either HER2-positive and/or had a Ki-67 LI 
>13% or both [84]. ER-negative tumors were classified either as HER2-positive or as 
TNBC (HER2-negative and PR-negative). Cases with casting-type microcalcification 
on the mammogram were also included in the study because these tumors have been 
reported to have an unfavorable outcome by some authors [85-87], and they are 
considered as a special entity by the multidisciplinary breast team at the University of 
Szeged. During the analysis of the cases, we observed a consistent and strong staining 
for GHRH-R in foci of apocrine metaplasia (Figure 3). To investigate this 
unanticipated phenomenon, we included 31 cases of recently diagnosed carcinomas 
(of any size) with apocrine differentiation (apocrine carcinomas). For the selection of 
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apocrine neoplasms, we defined apocrine differentiation by using both 
histomorphologic [3] and IHC criteria (ER and PR negativity, AR and GCDFP-15 
positivity) [16]. 
 
Figure 3. Strong staining for GHRH-R in foci of apocrine metaplasia (GHRH-R, 10x) 
 
FFPE tissue blocks (from the Departments of Szeged, Kecskemét and Turin) 
were used for the construction of composite TMA blocks. Every tumor was 
represented by multiple cores. The TMA block built up in Turin consisted of triplicate 
cores of 1.1 mm in diameter, whereas the TMA blocks in the Hungarian departments 
were assembled using duplicate cores of 2.2 mm in diameter. Samples were 
preferentially taken from the periphery of the tumors in every institution. At the 
Hungarian departments each TMA block included two orientation markers; two cores 
of non-mammary tissues (liver and kidney) also serving as negative controls, whereas 
in the TMA block built in Turin, four orientation cores were placed, two pieces of 
non-apocrine normal mammary tissue as negative controls and two cores of apocrine 
DCIS as positive controls. Six tumors were assessed in whole tissue blocks and two in 
needle core biopsy samples. (One of the cases assessed in whole section represented 
an apocrine DCIS with no evidence of invasive component but having a lymph node 
metastasis. This case was analyzed on the basis of both the tumor and its metastasis.) 
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Metastatic cancer tissues of lymph node positive cases were also evaluated 
with TMA technique using duplicate cores of 2.2 mm in diameter. 
The primary antibodies and IHC protocols used are listed in Table 1. The 
stains for ER, PR, HER2 and in most cases Ki-67 were performed routinely and the 
results were available from the original reports. The interpretation of the ER, PR and 
HER2 staining was according to the American Society of Clinical Oncology/College 
of American Pathologists guidelines [88, 89]. Every slide included a pituitary gland 
tissue-chip to serve as positive control. Specimens were evaluated only in the case of 
adequate staining in the controls. Positive staining of breast cancer tissue was 
classified according to the localization of immune reaction and percentage of positive 
tumor cells. On the basis of a previous report, both nuclear and cytoplasmic stainings 
were accepted as positive [33]. The invasive parenchymal component of the tumors 
was evaluated, using a lower and higher cutoff level of 10% and 50% of tumor cell 
positivity. 
Statistical analysis was performed with the chi-square test using the SPSS 20.0 
(IBM, Armonk, NY, USA) statistical software, and the significance level chosen was 
p < 0.05.  
 
3.3. p40 EXPRESSION IN BASAL-LIKE BREAST CARCINOMAS AND 
p40 AS A MYOEPITHELIAL MARKER IN BREAST LESIONS 
 
Groups of different histological types of breast lesions documented to 
demonstrate occasional alteration of MEC phenotype, including benign sclerosing 
lesions [90], DCIS [91] and adenomyoepithelial lesions were randomly selected on 
the basis of their diagnoses, and associated normal breast tissue was analyzed. 
Randomly selected consecutive TNBCs expressing high molecular weight CK 
5, corresponding to a subset of BLBCs on the basis of the surrogate IHC approach 
described by Nielsen et al [92] were used to build up a double TMA consisting of 20 
carcinomas in duplicate cores of 2.2 mm in diameter. The cores were taken from the 
periphery of the tumors as much as possible to avoid the central necrotic areas often 
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present in these cancers. Two orientation markers of non-mammary tissues (liver and 
kidney serving as negative controls) were also included, and at least one of the cores 
was taken from a part of a tumor including normal lobules or ducts to serve as 
positive controls for MEC markers. One sample was consistently damaged and 
uninterpretable on all slides and in both cores, and was therefore excluded from all 
analyses. 
The primary antibodies and protocols used for the IHC are listed in Table 1. 
The anti-p40 antibody is designed to selectively recognize the p40 isotype, whereas 
the anti-p63 antibody was developed using an immunogen incorporating the TA 
domain and is stated to recognize all isotypes of p63 (being a “pan p63” marker) 
according to the respective manufacturers’ data sheets provided with the antibodies. 
 
3.4. CD10 EXPRESSION IN APOCRINE LESIONS OF THE BREAST 
 
In this retrospective study, FFPE tissue blocks of 50 apocrine breast lesions 
were randomly selected including benign, in situ and invasive lesions. The protocol of 
the anti CD10 IHC used is detailed in Table 1. IHC stainings were carried out on 44 
whole tissue sections (thickness: 4–5 μm) and a TMA composite block composed of 
2.2 mm diameter cores in duplicate and partial overlap with the whole slide 
assessment. Statistical calculations were made with GraphPad QuickCalcs (San 
Diego, California). 
 
4. RESULTS 
 
4.1. GHRH-R IN DIFFERENT TYPES OF BREAST CARCINOMAS 
 
99 early breast cancer patients with 100 tumors (one bilateral case) were included in 
the present study. Cytoplasmic, nuclear, or combined GHRH-R positivity was 
detected in 54/100 (0.54) and 28/100 (0.28) of the cases using 10% and 50% cut-off 
values, respectively. Considering the most common histological types, ILCs displayed 
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GHRH-R positivity significantly more often (10% cut-off: p = 0.03; 50% cut-off: p = 
0.0003 Pearson’s chi-square) than ductal/NST carcinomas lumped together with 
tubular carcinomas (Table 2, Figure 4.). Seven of the ILCs were pleomorphic on the 
basis of cellular morphology and combined histological grade 3; all but one case were 
positive for GHRH-R. Positivity of staining according to the histological grade of the 
tumors is shown in Figure 5. Interestingly, the highest proportion of tumors 
demonstrating GHRH-R positivity was seen in grade 2 carcinomas, whereas this 
proportion was lower for grade 1 and grade 3 tumors (Table 2). Statistical analysis of 
GHRH-R expression in different tumor grades with the Pearson’s chi-square test 
failed to give a significant result (p = 0.0527) when using the 10% cut-off, but it was 
possible to get significant result applying the 50% cut-off level (p = 0.001). 
  
Figure 4. Distribution of GHRH-R-positive and GHRH-R-negative cases according 
to different cut-off values in different histological types of breast carcinomas. 
 
Figure 5. Distribution of GHRH-R-positive and GHRH-R-negative cases according 
to different cut-off values in different grades of breast carcinomas. 
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To assess the relation of GHRH-R expression and proliferation, the mitotic 
score was used, as an ordinal variable standardizing mitotic counts to the area of the 
high power field of the microscopes, but no association was found. On the other hand, 
although there was no significant difference in the Ki-67 LI of GHRH-R positive and 
negative tumors with the 10% cut-off level, statistical analysis using the 50% cut-off 
yielded a significant difference (10% cut-off: p = 0.0934; 50% cut-off: p = 0.0455; 
single sample t-test), albeit we need to note that Ki-67 LIs were available in only 70 
cases (Figure 6.). There was no statistically significant association between nodal 
status and GRHR-R staining (10% cut-off: p = 0.167; 50% cut-off: p = 0.332; 
Pearson’s chi-square) (Table 2). 
 
Figure 6. Average Ki-67 LIs (%) of GHRH-R-positive and GHRH-R-negative cases. 
 
 
Figure 7. Distribution of GHRH-R-positive and GHRH-R-negative cases according 
to different cut-off values in different molecular subtypes of breast carcinomas. 
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As concerns the molecular types according to the IHC based classification 
(10% cut-off: p = 0.009; 50% cut-off: p = 0.00001 Pearson’s chi-square), the luminal 
B-like category emerged as the molecular subtype with the highest ratio of positive 
cases (Figure 7). The only luminal B-like tumor with negative GHRH-R status was a 
HER2-negative carcinoma with high proliferation rate (Ki-67 LI: 25%). A substantial 
number (8/26, 31%) of triple-negative cases showed GHRH-R positivity in 10-50 % 
(average: 25%) of the tumor cells, but there were no cases (except the apocrine 
carcinomas) exceeding the 50% cut-off level (Table 2, Figure 7). 
As a special clinical entity, 12 tumors with casting-type microcalcifications on 
the mammogram were also included in the study. Although a higher percentage of 
these cases showed GHRH-R positivity compared to NST carcinomas without casting 
type calcification (Table 2), the statistical analysis showed no significant correlation 
(10% cut-off: p = 0.1092; 50% cut-off: p = 0.2030 Pearson’s chi-square). The 
carcinomas with casting-type calcifications histologically represented ductal/NST 
carcinomas with high-grade DCIS showing comedo necrosis. These tumors were 
heterogeneous in terms of hormone receptor (seven were ER-positive and five of 
these were also PR-positive) and HER2 status (four were positive). The GHRH-R-
negative cases belonged to the luminal A (n = 2) or the HER2-enriched (n = 1) types.  
All the apocrine carcinomas studied were negative for ER and PR; 21 of them were 
HER2-negative, 3 were 2+ on IHC and not tested by ISH, whereas 6 tumors were 
positive for HER2 and one case of apocrine DCIS was not tested for this marker. The 
striking majority of breast carcinomas with apocrine differentiation (10% cut-off: 
97%, 50% cut-off: 90%) showed strong GHRH-R positivity. 
Twenty-two previously examined GHRH-R expressing primary node positive tumors 
were evaluated. Two cases were unavailable for testing as the only metastatic sentinel 
node was entirely sectioned following the Hungarian recommendation for the work-
up of these lymph nodes. Only a single case proved to be totally negative, and 70% 
(14/20) of the cases showed positivity in more than 10% of the tumor cells, whereas 
30% (6/20) in more than 50% of the tumor cells. 
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Category Positive/Total No. of 
cases 
Percent of positive cases (95% 
confidence interval (CI)) 
10% 
cut-off 
50% 
cut-off 
10% cut-off 50% cut-off 
Histological 
type 
NST 25/56 8/56 45% (32-58%) 14% (7-26%) 
ILC 28/42 20/42 67% (52-79%) 48% (33-63%) 
Apocrine carcinomas  30/31 28/31 97% (84-99%) 90% (75-97%) 
Tumor 
grade 
Grade 1 5/13 3/13 38% (18-64%) 23% (8-50%) 
Grade 2 31/46 21/46 67% (53-79%) 46% (32-60%) 
Grade 3 18/40 4/40 45% (31-60%) 10% (4-23%) 
Molecular 
type 
Luminal A-like 22/42 14/42 52% (38-67%) 33% (21-48%) 
Luminal B-like 12/14 10/14 86% (60-96%) 71% (45-89%) 
HER2-enriched 8/13 2/13 62% (36-83%) 15% (4-42%) 
TNBC 8/26 0/26 31% (17-50%) 0% (0-13%) 
Lymph 
node status 
Node positive 22/30 11/30 73% (56-86%) 37% (22-54%) 
Node negative 34/60 16/60 57% (44-68%) 27% (17-39%) 
Axillary lymph node metastasis of 
GHRH-R positive primary tumors 
14/20 6/20 70% (48-85%) 30% (15-52%) 
NST with comedo DCIS and casting 
microcalcification  
9/12 4/12 75% (47-91%) 33% (14-61%) 
Table 2. Distribution of GHRH-R-positive and GHRH-R negative cases according to 
different cut-off values and different clinicopathological groups of breast carcinomas.  
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4.2. p40 EXPRESSION IN BASAL-LIKE BREAST CARCINOMAS AND 
p40 AS A MYOEPITHELIAL MARKER IN BREAST LESIONS 
 
Nineteen CK5-expressing TNBCs and thirty-six breast lesions with frequently 
altered MEC phenotype were included in the present study, and normal breast tissue 
was also evaluated in each case, where available on the selected slide (n = 31). The 
analyzed breast lesions were as follows: 10 adenomyoepithelial lesions [including 9 
adenomyoepitheliomas (AME) and 1 adenomyoepithelial adenosis], 13 high-grade 
DCIS with attenuated/flattened MEC layer and 11 sclerosing lesions (including 10 
complex sclerosing lesions and 1 complex fibroadenoma with areas of sclerosing 
adenosis). In all the cases, where appropriate (31/31), a general diffuse strong nuclear 
p40 positivity was detected in normal terminal ductulolobular units (TDLU) around 
the lesions. p40 and p63 staining patterns showed no difference in regular TDLUs 
(Figure 8 a, b). 
 
Figure 8. Parallel p40 (A, C) and p63 (B, D) staining patterns of MEC around DCIS 
and in AME. A, B: DCIS with scant, flattened, IHC-positive MEC in the top left of 
each panel (insert) and without IHC-positive MEC in the lower left of each panel; 
note the contrasting strong and diffuse staining of MEC around normal structures 
(right of each panel). C, D: AME with rather diffuse and strong staining with both 
markers. (A–D ×40.) 
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All adenomyoepithelial lesions showed nuclear p40 positivity in the MEC 
component ranging from weak focal (5/10) to strong diffuse (5/10). No conspicuous 
difference between p40 and p63 reactivity was noted (Figure 8 c, d). The 
attenuated/flattened MEC around DCIS showed somewhat weaker nuclear staining 
compared with surrounding normal TDLU, and negative cells with unequivocal MEC 
morphology were also detectable (Figure 8 a, b). Rarely, ducts affected by DCIS 
showing no positivity of the MEC were also recognized. In this set of lesions, MEC 
stained practically in an identical manner with p40 and p63. In 2 cases, focal 
positivity (few cells in an ER and PR negative but HER2-overexpressing in situ 
carcinoma and up to 10% in a triple-negative one) was detected in the epithelial cells 
of the DCIS using p40 IHC, whereas p63 staining was weaker in the first and barely 
perceptible (requiring high-power inspection for detection) in the second case. All 11 
sclerosing lesions displayed p40 positivity of inconstant intensity, which was usually 
weaker than in the endogenous normal TDLUs serving as control. Focally negative 
MEC were also visible in multiple cases. The p63 and p40 reactions were again 
identical in pattern and intensity (Figure 9). 
 
Figure 9. Staining of MEC with p40 (A, C) and p63 (B, D) in sclerosing lesions. MEC 
are nicely highlighted with the two stains in both the distorted sclerosing glands (A, 
B: top right area) and the non-distorted glands (elsewhere), but show parallel 
diminished staining around the centrally located apocrine glands. (A, B ×20; C, D 
×40) 
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Of the 19 CK5-expressing TNBCs, 8 showed some p63 positivity, ranging 
from a few cells to 70% of the tumor cells. The intensity was generally weak and in 
many cases detection required scrutinous search; the intensity of staining was strong 
in 1 case only (Figure 10a). In contrast, p40 positivity could be seen in the majority of 
the cases (18/19) ranging from a few cells (<1%) to 70%. The intensity was either 
similar to that seen with p63 or stronger (Figure 10). 
 
 
Figure 10. Staining of CK5-expressing TNBC cells with p40 (A, C) and p63 (B, D). 
A, B: Similar staining in the case demonstrating the most labeled cells and the 
strongest positivity with both antibodies. Staining of some cells with p40 (C) and lack 
of staining with p63 (D) in another case. A, B ×5. C, D ×200 (from digital slides). 
 
4.3. CD10 EXPRESSION IN APOCRINE LESIONS OF THE BREAST 
 
Fifty apocrine lesions were included in the study: 10 cysts with or without 
papillary hyperplasia, 1 cyst without an MEC layer [93], 6 apocrine adenoses, 2 
papillomas, 13 DCIS, 14 invasive ductal/NST carcinomas and 4 ILCs. 17/19 [0.89; 
95% CI 0.68–0.97] benign apocrine lesions (Figure 11) showed complete or partial 
luminal CD10 staining (Figure 12a), although most cases included parts without 
staining and 2 lesions (an apocrine adenosis and a cyst with papillary hyperplasia) 
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were completely negative. The MECs in benign lesions were often but not always 
positive. 
As concerns malignant lesions, 8/13 apocrine DCIS cases displayed no 
luminal staining (Figure 12/b), but 4 (0.31; 95% CI 0.13–0.58) demonstrated very 
focal luminal positivity. The MECs around the DCIS showed a spectrum of staining 
from nil to strong complete. Only 4/18 (0.22; 95% CI 0.09–0.46) invasive carcinomas 
demonstrated luminal/ membranous staining (Figure 12/c). Cytoplasmic CD10 
positivity was seen focally in 4 invasive cancers (Figure 12/d) and in 3 DCIS, and 
more markedly in 1 invasive carcinoma NST (Figure 12/c); 2 of these and 1 in situ 
carcinoma with ‘aberrant’ cytoplasmic staining demonstrated no membranous 
staining. Benign lesions showed luminal/membranous staining more commonly than 
malignant ones (17/19 vs. 8/31; p < 0.0001, chi-square test with Yates correction for 
continuity) and this was also true for any epithelial staining including aberrant 
cytoplasmic labeling (17/19 vs. 11/31; p = 0.0006, chi-square test with Yates 
correction for continuity). 
 
 
Figure 11. Proportion of benign lesions, in situ and invasive cancers showing 
luminal/membranous CD10 positivity. The bars represent 95% CIs. 
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Figure 12. Examples of CD10 positivity in different lesions. A: Apocrine cysts with 
areas of papillary hyperplasia. Note focal to near-complete luminal epithelial and 
strong MEC positivity. B: DCIS with a lack of luminal/membranous staining in foci 
of lumen formation and weak MEC labeling. C: Luminal and strong cytoplasmic 
staining in invasive carcinoma NST. D: Very focal cytoplasmic labeling in invasive 
carcinoma. (×10) 
 
5. DISCUSSION 
 
5.1. THE EXPRESSION OF GHRH-R IN DIFFERENT TYPES OF 
BREAST CARCINOMAS 
 
The endocrine effect of GHRH on cancer has been thought to be rendered by 
the stimulation of the GHRH/GH/IGF-1 axis. Recently, an additional 
autocrine/paracrine role in the regulation of proliferation and differentiation of cancer 
cells has been proposed. The latter mechanism is supported by the presence of GHRH 
in various malignancies as demonstrated by means of mRNA expression, by the 
detection of immuno-reactive and biologically active GHRH and by the identification 
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of its receptors in different human cancers [21-24, 32]. GHRH antagonists have been 
tested as potential targeted therapeutic agents in several malignancies, including 
breast cancers [26, 30, 31]. The incidence of GHRH-R expression in different breast 
cancer subtypes (histological, molecular and clinical) has not yet been investigated 
extensively. Since the presence of the GHRH-R could be a selection criterion for 
potential treatment targeting the GHRH-R, it was thought that a study identifying 
potential subsets of tumors preferentially expressing the receptor could be of 
relevance. To elucidate the possible presence of GHRH-R in the individual subtypes, 
we selected tissue blocks of different histological and molecular types from our 
archives, and examined the expression of GHRH-R with IHC. As concerns the 
different histologic types of breast cancer, there are many based on special features, 
but the two major types are ductal/NST carcinomas and ILCs. Other subtypes are less 
frequent, and are sometimes viewed as special types of ductal (non-lobular) 
carcinomas. In our study, ILCs were significantly more frequently positive for 
GHRH-R. A previous report has identified ILCs to have a higher rate of GHRH 
expression (a phenomenon which could support an autocrine/paracrine regulatory 
effect) than ductal/NST carcinomas. The same study failed to document a similar 
predilection for the distribution of SV1 using a polyclonal antibody, which is no 
longer available [25]. In that study, only 1 of 6 ILCs was positive for SV1. The 
contrary finding that a significant number of ILCs tested were positive for GHRH-R 
in our analysis, could probably be explained by the use of a different antibody that 
detects both the pGHRH-R and the SV1 receptor. Since the GHRH-R antibody used 
in our study was raised against a synthetic peptide derived from the C-terminal 
domain of the human pGHRH-R [Product datasheet - ab76263], and the biologically 
active SV1 differs from the full length pituitary receptor only in its N-terminal part 
[22], the antibody recognizes the full length GRHR-R along with the SV1, but not the 
much shorter (145-amino acid-long) SV2. 
As concerns the grade of differentiation, significant association with the 
GHRH-R status was just found using the 50% cut-off value, and grade 2 tumors 
seemed to show GHRH-R positivity more frequently than grade 1 or 3 tumors. 
Reports on the distribution of GHRH-R by grade are scarce. Chatzistamou et al. 
suggested no predilection for any level of differentiation: 2/2 of grade 1, 5/16 of grade 
2, and 6/22 of grade 3 ductal/NST carcinomas were identified as positive [25]. The 
reasons for finding more positive cases among grade 2 tumors are not clear, and could 
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be coincidental, especially in the light of molecular studies. Sotiriou and colleagues 
have demonstrated that gene expression profile-based genomic grades matched well 
histological grades 1 and 3, but breast tumors classified as histological grade 2 fell 
either into the category of low or high genomic grade [94]. Therefore, histologic 
grade 2 tumors cannot be classified morphologically into high or low grade, resulting 
in an intermediate prognosis due to this dual composition. Our results, as well as the 
previous report cited, suggest that GHRH-R positivity can occur in any grade of 
breast cancer, and there seems to be no strong correlation of GHRH-R expression 
with histologically determined tumor grade. In keeping with the results relating to the 
differentiation of the carcinomas, an ambiguous relation was found with proliferation 
depending on whether assessed by mitotic scores or the Ki-67 proliferation marker. 
Although there was no association between GHRH-R expression and mitotic scores, a 
significant correlation was found using the Ki-67 LIs. The significant association of 
tumor grade with the GHRH-R status using the 50% cut-off and the differences 
between the statistical analysis of mitotic scores and Ki-67 LIs suggest that the 
equivocal results may be due to the shortcomings of conventional histological 
grading, and maybe a stronger correlation could be found using genomic grades. 
There was no association of GHRH-R expression and the nodal status of breast 
carcinomas. The study also incorporated 12 cases with casting-type microcalcification 
on the mammogram. The clinical outcome of this entity is still subject to some debate 
with some authors and results reinforcing the finding of a poor outcome [85-87, 95-
97] and others refuting it [98, 99]. Our experience supports the poor outcome of these 
tumors [87], and this is why such cases were separately studied for their GHRH-R 
expression. Although the authors originally describing this entity as one associated 
with poor prognosis did not specifically report the distribution of this type of 
carcinoma presentation according to molecular subtypes, they suggested that many of 
these tumors were HER2-positive [95], with HER2 positivity being three times more 
frequent in this subgroup than in breast carcinomas without casting-type calcifications 
[Tot T., personal communication 2013 July]. The present series of small tumors 
included carcinomas with casting-type microcalcifications with heterogeneous grade 
and molecular type distribution, and only one-third were HER2-positive. All cases 
with casting-type calcifications were associated with high-grade DCIS showing 
comedo necrosis and microcalcification. Using the 50% cut-off, GHRH-R positivity 
was observed in 33% of the cases of this clinical/mammographical entity, which is 
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more than double of the 14% positivity rate of ductal/NST carcinomas without 
casting-type microcalcification; however this difference failed to be statistically 
significant. The relevance of these findings is not yet known, but further study is 
warranted to clarify this issue. GHRH-R positivity was seen in all molecular types of 
breast cancer, including ER-positive and ER-negative cases, in keeping with results 
found with cell lines [31]. The majority of the luminal B-like tumors demonstrated 
strong and diffuse immune reaction with anti-GHRH-R, but as even luminal B-like 
tumors are heterogeneous, the significance of this finding in a relatively low number 
of cases is uncertain. Even though TNBCs showed GHRH-R positivity in a relatively 
low percentage of tumor cells (5-30%, average: 15%) and cases (31% using 10% cut-
off), the unfavorable prognosis and the limited therapeutic modalities for these 
carcinomas emphasize the importance of this finding. Targeted anti-GHRH therapy 
proved to be efficient in the treatment of nude mice transplanted with human TNBC 
xenografts [100, 101]. An unfortunate observation was the lack of diffuse GHRH-R 
expression in this molecular group with no cases showing positivity in more than half 
of the tumor cell population. Further investigations are necessary to clarify whether 
TNBCs expressing the GHRH-R could be treated with GHRH-R antagonists. Whether 
the issue of scattered positivity highlights a limited utilisability of a possible anti-
GHRH-R treatment or such low positivity rates as in the case of ER or PR could be 
considered enough should also be investigated in the future. 
Regarding metastatic breast cancer, axillary lymph node metastases of the 
GHRH-R expressing primary node positive tumors were evaluated. The fact that no 
distant hematogenous metastases were available for testing could be explained by the 
early stage of the primary carcinomas examined. Although we noticed varying degree 
of GHRH-R staining decrease of the metastases compared to the primary carcinomas, 
only a single case showed total loss of GHRH-R expression, which is an important 
observation if we consider that any future targeted therapy looks more promising if it 
could also help in advanced cases. 
During the analysis of the cases, we noticed a pronounced, uniform GHRH-R 
expression in cysts showing apocrine metaplasia. This finding inspired us to 
investigate the expression of GHRH-R in cancers showing apocrine differentiation 
and to include 31 cases of apocrine carcinoma (both in situ and invasive tumors). 
With 10% cut-off, 97% demonstrated strong and diffuse positivity, whereas using 
50% cut-off, 90% were found positive. Apocrine carcinomas are defined as 
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carcinomas in which the cells demonstrate the cytological features of apocrine cells 
[3], they are often ER-negative and PR-negative, but AR-positive tumors [16], and 
express apocrine markers like GCDFP-15. As concerns the molecular types 
approached by IHC, somewhat more than half of apocrine carcinomas represent a 
subgroup of TNBCs and nearly half of them overexpress HER2 [17]. A molecular 
apocrine type of breast cancer with increased androgen signaling has also been 
described, and is characterized by ER negativity and AR positivity [3, 18, 102, 103]. 
This latter type is lately referred to as the LAR subtype of TNBC [19]. The overlap 
between breast cancers classified as apocrine on the basis of gene expression profile 
versus morphologic features is not complete. It has been estimated that the apocrine 
gene expression profile may be present in 8–14% of breast cancers, whereas apocrine 
carcinomas classified on the basis of morphologic appearance are relatively rare, 
comprising about 4% of breast carcinomas [3]; part of them may be a subset of 
TNBCs. Their androgen-dependent signaling pathway could also suggest a specific 
treatment. Whether their homogeneous positivity for GHRH-R can be translated to a 
targeted therapy with GHRH-R antagonists, which are under development for clinical 
use requires further studies. 
As a caveat, it must be remembered that the present study included non-
consecutively diagnosed breast carcinomas, and therefore the proportion of positive 
tumors may only be an estimate, requiring confirmation on a larger group of tumors. 
A strength, however, is that we chose to limit tumor heterogeneity by studying 
relatively small cancers. 
 
5.2. p40 EXPRESSION IN BASAL-LIKE BREAST CARCINOMAS AND 
p40 AS A MYOEPITHELIAL MARKER IN BREAST LESIONS 
 
The identification of an outer MEC layer is a valuable clue in the differential 
diagnosis of breast lesions. A broad spectrum of different cytoplasmic (e.g. smooth 
muscle actin (SMA), smooth muscle myosin heavy chain (SMMHC), calponin, S100 
or CK5/6), nuclear (e.g. S100 and p63) and membranous (e.g. CD10) MEC markers is 
used by reporting pathologists. p63 protein is a commonly used MEC marker. Due to 
its high sensitivity (90%) and even superior specificity (up to 100% in normal TDLU) 
reported [45], it is preferred to cytoplasmic markers (SMA, calponin and SMMHC), 
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as the latter may also variably react with vascular smooth muscle cells and 
myofibroblasts [48]. The specificity of p63 is somewhat diminished by the 
observation that it is rarely expressed by tumor cells of NST carcinomas [48]. 
Reduced expression of markers in MEC associated with DCIS and complex 
sclerosing lesions is a documented phenomenon [90, 91], and such an alteration in the 
MEC phenotype has also been reported in AME [104]. Some markers (CD10, CK5/6 
and SMMHC) show reduced expression more frequently than others (p63, SMA and 
calponin) [90, 91]. 
This study specifically focused on lesions that have been reported to 
demonstrate an altered MEC phenotype, i.e. a change in the expression of MEC 
markers compared with MEC of the normal breast parenchyma: sclerosing lesions 
[90], high-grade DCIS [91] and adenomyoepithelial lesions [104]. Our results suggest 
that p63 and p40 perform similarly in all these settings. In normal breast tissue, MEC 
are nicely highlighted by both antibodies, and when the expression of one is reduced 
in a pathological condition, the other shows a similar reduction in expression; focal 
losses of expression occurred in parallel. Although p40 has been reported to have 
superior specificity than p63 as a squamous cell carcinoma marker in the differential 
diagnosis of non-small cell lung cancer [49], it seems to perform similarly in breast 
lesions acknowledged to show altered expression of MEC markers. It is, therefore, 
suggested that both antibodies can be used interchangeably for the demonstration of 
MEC. A recent study performing a TMA analysis of a larger number of breast lesions 
[32 adenoses, 34 intraductal papillomas, 31 DCIS, 257 ductal/NST carcinomas and 36 
metaplastic carcinomas] with monoclonal pan-p63 and polyclonal p40 antibodies 
from different sources (but with an identical clone and identical target epitopes, 
respectively) reached a similar conclusion regarding the corresponding staining of 
MEC with p63 and p40 antibodies [105]. However, despite the identical epitopes used 
to generate the polyclonal p40 antibodies, one of the two tested (Diagnostic 
Biosystems, Pleasanton, Calif., USA) showed a much higher proportion of cancer cell 
labeling, highlighting the different sensitivities and specificities of the two antisera. 
This latter antibody was also less specific for MEC in DCIS. On the basis of the 
surrogate IHC based molecular classification, the highest proportion of p63 or p40 
staining was found in TNBCs [105]. Identical staining of MECs with monoclonal p63 
and p40 antibodies was also reported in a small series of 10 breast excision specimens 
[106]. 
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The fact that the p63 antibody we used (a pan-p63 marker) should 
theoretically label more cases than the p40 antibody identifying only the ΔNp63 
isoforms makes our finding of a higher rate of cancer cell labeling with p40 somewhat 
enigmatic. The explanation may perhaps lie in the differences in sensitivities alluded 
to in the previous paragraph in connection with two polyclonal p40 antibodies. 
However, the small sample size, a limitation of the present study, may also play a 
role. 
In conclusion, p40 seems to be similar to p63 as an MEC marker both in 
normal breast tissue and in lesions with observed alterations in the MEC 
immunophenotype. The presence of tumor cell positivity in NST carcinomas 
demonstrating an IHC staining profile mostly in keeping with a BLBC did not 
interfere with MEC detection but should be acknowledged, and the preference of p40 
for highlighting this subset of carcinomas rather than other subtypes should be further 
investigated. 
The molecular subtype of breast cancer carries valuable information and can 
help to predict prognosis and determine the appropriate therapy. As long as 
determination of molecular subtypes based on gene expression profiling is not yet 
available in routine histopathology practice, surrogate IHC methods are expansively 
used for the molecular classification of the cases. Using the IHC based method, 
BLBC is defined as an ER, PR and HER2 negative tumor expressing proteins usually 
found in basal/ myoepithelial cells of the normal breast. Although CK5 and EGFR are 
the most frequently used and accepted, other markers e.g. high-molecular-weight 
cytokeratins as CK6, CK14 and CK17, P-cadherin, CD117, nestin, p16 and p53 [107] 
can also be used alone or as a part of an IHC panel [108]. As concerns the p53 tumor 
suppressor gene family, both p53 and p63 expression can be used as markers of basal 
phenotype. The anti-p53 antibody has a specificity of 80-85% and a sensitivity of 50-
60% [109, 110], whereas the detection of the p63 protein expression is reported to 
have a very high specificity (94%), but low sensitivity (14%) [108]. The anti-p63 
antibody is also useful in the diagnosis of metaplastic breast cancer particularly in the 
case of the squamous/spindle cell variant [111, 112]. A relatively newly discovered 
member of the p53 gene family, the p40 isoform of the p63 protein, was recently 
introduced as a commercially available antibody and was not previously tested in 
BLBC. One obvious difference between the staining patterns of p63 and p40 is the 
different proportion of focal positivity in carcinoma cells. CK5-expressing TNBCs 
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seem to express p40 more frequently than p63. Whether this phenomenon is restricted 
or preferential in BLBCs expressing CK5 has not been examined, and is the subject of 
an ongoing investigation, but one of the DCIS cases showing a few p40- and p63-
positive cells was a HER2-overexpressing lesion. 
 
5.3. CD10 EXPRESSION IN APOCRINE LESIONS OF THE BREAST 
 
The fact that CD10 is a ubiquitous enzyme found on the surface of many 
different normal cell types and pathologic lesions has a negative impact on its 
specificity and thus on its possible utility in routine histopathological differential 
diagnosis. Therefore, CD10 IHC reactions should be only used to answer specific 
differential diagnostic questions in well-known circumstances. 
Overall, breast epithelium rarely expresses CD10. Only focal labeling of 
luminal ductal epithelium was reported by Kalof et al. [81]; the limited number of 
invasive and in situ carcinomas (n = 46) that they studied were all negative. Bains and 
Sidhu [113] reported on a case of invasive breast carcinoma, showing cytoplasmic 
CD10 staining associated with an in situ component and intraductal papilloma, 
demonstrating the same type of labeling. Although no mention of receptor status was 
included in their description, on the basis of the figures, none of these lesions 
demonstrated the characteristic apocrine morphology. The authors concluded that 
CD10 positivity in metastatic tumors cannot rule out the breast as primary, and related 
the phenotype to the CD10-positive progenitor cells capable of differentiating towards 
luminal epithelial cells and MECs described by Stingl et al. [114]. NST carcinomas 
and ILCs are rarely positive for CD10 [83], but some subsets may be different in this 
respect: of 40 ER-positive tumors, none demonstrated CD10 positivity (defined with a 
cut-off of 10% staining) and only a single case showed <10% labeling, whereas 12 of 
77 ER-negative carcinomas (16%) showed cytoplasmic or membranous staining in 
30–100% of the cells [115]. A subset of ER-negative breast cancers is also negative 
for PR and HER2, and is therefore labeled as TNBC. Some TNBCs express basal (i.e. 
MEC) markers (CK 5 and/or EGFR) and this feature has been suggested for the 
delineation of the BLBC subgroup of breast cancers on IHC [92]. Not surprisingly, 
some of these carcinomas may also express CD10, an MEC marker in a substantial 
number of cases (16/20 of spindle-cell metaplastic carcinomas and carcinosarcomas) 
[116], similarly to the rare cases that demonstrate straightforward myoepithelial 
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differentiation [117]. Apocrine carcinomas are also generally ER- and PR-negative 
[118], and might have been included in previous studies of ER-negative carcinomas, 
but without distinct identification of this subset. Smollich et al. [119] identified 
cytoplasmic (and occasional membranous) CD10 (neprilysin) staining of tumor 
parenchymal (epithelial) cells in 33/126 (26%) of breast cancers and found this 
labeling to be associated with better prognosis, in contrast to the CD10 staining of the 
stromal myofibroblast reported to indicate worse prognosis. 
CD10 positivity has been described in benign apocrine epithelium [81, 83], 
but no data on CD10 expression in various other types of apocrine breast lesions have 
been available until now. Our results indicate that benign apocrine epithelium 
(metaplasia) is typically positive for CD10 with a luminal staining pattern, although 
there are exceptions to the rule. Malignization or apocrine differentiation in malignant 
lesions seems to be associated with a partial or complete loss of this staining pattern, 
which is therefore rarer in in situ carcinomas and even rarer in invasive ones, and 
cytoplasmic (aberrant) staining may also occur in this subset. 
Although the staining of MECs was not the primary aim of our study, our 
findings are in keeping with earlier works on the subject, and suggest that the 
sensitivity of CD10 as an MEC marker is lower than that of other markers like p40 
and SMA. Its proportional sensitivity is even further diminished in certain lesions like 
benign sclerosing lesions [90] and DCIS [91], known for their reduced expression of 
MEC markers. Based on the literature [81, 91] and supported by our experience, 
CD10 is not an ideal MEC marker. However, occasional CD10 staining of epithelial 
cells should be kept in mind, as its occurrence may interfere with the identification of 
some cells as epithelial or myoepithelial, especially in apocrine lesions, some of 
which may turn out to be benign, even without the presence of a MEC layer [93]. 
 
6. CONCLUSIONS 
 
Our work demonstrates that the distribution of GHRH-R among breast 
carcinomas is not restricted to histological type, differentiation grades or molecular 
subtypes. ILCs were found to express this marker more frequently than ductal/NST 
carcinomas. The finding of a relatively high proportion of positivity among 
ductal/NST carcinomas with casting-type microcalcification is of uncertain 
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significance. Even though TNBCs showed GHRH-R positivity in a relatively low 
percentage of tumor cells (5- 30%, average: 15%) and cases (31% using 10% cut-off), 
with no cases showing positivity in more than half of the tumor cell population, the 
unfavorable prognosis and the limited therapeutic modalities available for these 
patients highlight the importance of this finding, which is further emphasized by the 
fact that targeted anti-GHRH-R therapy proved to be efficient in the treatment of nude 
mice transplanted with human TNBC xenografts. The most remarkable finding of this 
study, we feel, is that apocrine epithelium (both benign and malignant) stains 
diffusely and strongly for GHRH-R. However, the genuinity of our related results 
require confirmation, and we have started further investigation of apocrine tumors by 
courtesy of a grant sponsored by the University of Szeged. 
Whether our findings can be used for targeting breast carcinomas with GHRH-
R antagonists is to be clarified in future studies. 
 
The p40 protein seems to be similar to p63 as a MEC marker both in normal 
breast tissue and in lesions with observed alterations in the MEC immunophenotype. 
The presence of tumor cell positivity in NST carcinomas demonstrating an IHC 
staining profile mostly in keeping with a BLBC did not interfere with MEC detection 
but should be acknowledged, and the preference of p40 for highlighting this subset of 
carcinomas rather than other subtypes should be further investigated. 
 
CD10 positivity is luminal/membranous in most benign apocrine lesions, the 
staining being non-universal and sometimes focal. Analogous staining in apocrine 
malignancies seems rarer in DCIS and even rarer in invasive apocrine carcinomas, but 
atypical cytoplasmic positivity may also occur. CD10 is not an ideal MEC marker in 
apocrine lesions. When using CD10 immunohistochemistry as a MEC marker or in 
the case of a carcinoma of unknown primary it should be important to know that 
benign and malignant apocrine lesions of the breast can also express CD10. The fact 
that CD10 is a ubiquitous enzyme found on the surface of many different normal cell 
types and pathologic lesions has a negative impact on its specificity and thus on its 
possible utility in routine histopathological differential diagnosis. Therefore, CD10 
IHC reactions should be only used to answer specific differential diagnostic questions 
in well-known circumstances. 
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